And that is one of the reasons that we’ve decided to conduct the INSIGHT study and seek a label in the second line is to be able to promote to that use upon approval. Your second question, I think Brad was related to vimseltinib and our announcement this morning that we expect to complete enrollment in the first quarter of this year and read out the study in Q4. And your question was around the timing for a potential NDA. So it’s really premature for us to share our thoughts around what the timing could be for an NDA post top line readout. What I can say is that our team has demonstrated with €“ certainly with QINLOCK and our fourth line label, our ability to quickly move from topline data readout to get a filing in. This will be no different.
And when we have a readout of the study of the topline results, I’m sure we’ll be in a position of that time to offer some additional color around what the timing could be for a potential filing in the U.S. and filings outside of the U.S.
Operator: Our next question comes from Peter Lawson with Barclays. Your line is now open.
Peter Lawson: Great. Thank you. Thanks for taking my questions. Just from NCCN guidelines for GIST, are you looking to gain guideline inclusion for exon 11, 17, 18?
Steve Hoerter: Yes. Thanks for the question, Peter with respect to NCCN. So we’re going to continue to monitor what NCCN decides to do with respect to any guideline update, and that will guide our decision about any future submissions of data. So that’s the approach that we plan on taking with respect to NCCN going forward.
Peter Lawson: Got you. Does €“ I mean, does the exon 11, 17, 18 data plus various other mutations, doesn’t that make the NCCN guideline changes the second line will come as difficult for them to make that judgment call?
Steve Hoerter: Yes, I think what we’ve learned Peter from the analysis is that there’s a level of complexity and nuance I think to the data. I mean, certainly the 11, 17, 18 population, the result is very clear in terms of QINLOCK €“ the benefit of QINLOCK versus sunitinib. And we have this group of patients in whom ctDNA is not detectable where we see on the forest plot. The hazard ratio for PFS is virtually in the center of that forest plot. So I think it’s unclear at the moment what NCCN might choose to do. We know that physicians generally are interested in having more options available to treat their patients. We don’t think that this situation with just is any different. So we would expect that will be of interest to physicians on the panel as they think about providing options to patients going forward.
Peter Lawson: Got you. Thank you. And then just on China, just kind of the size of the opportunity how we should think about pricing and kind of how you think it could help revenues over the next couple of years, whether it’s 2023 or 2024?
Steve Hoerter: Sure. Margarida, would you like to address the China opportunity and Zai disclosures?
Margarida Duarte: Absolutely. Thank you. Thanks for the question, Peter. So we review this listing very positively as it’ll increase affordability and access for Chinese patients moving forward. So we do expect this to be a key contributor of volume growth over time how quickly that happens we do not have a lot of details yet. But all in all, we view these extremely positively.
Peter Lawson: Got you. Thank you so much.
